Chakiath Jose

2.0k total citations · 2 hit papers
9 papers, 1.2k citations indexed

About

Chakiath Jose is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Surgery. According to data from OpenAlex, Chakiath Jose has authored 9 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 7 papers in Radiation and 1 paper in Surgery. Recurrent topics in Chakiath Jose's work include Prostate Cancer Treatment and Research (7 papers), Prostate Cancer Diagnosis and Treatment (7 papers) and Advanced Radiotherapy Techniques (7 papers). Chakiath Jose is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Prostate Cancer Diagnosis and Treatment (7 papers) and Advanced Radiotherapy Techniques (7 papers). Chakiath Jose collaborates with scholars based in New Zealand, Australia and United Kingdom. Chakiath Jose's co-authors include Isabel Syndikus, David P. Dearnaley, Matthew R. Sydes, Christopher Scrase, John D. Graham, J. H. Matthews, Robert Huddart, Jeremy Millar, Mahesh Parmar and Edwin Aird and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and European Urology.

In The Last Decade

Chakiath Jose

9 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

2007 686 citations David P. Dearnaley, Matthew R. Sydes et al. The Lancet Oncology profile →
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

2014 344 citations David P. Dearnaley, Gordana Jovic et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Chakiath Jose

Since Specialization

Citations

This map shows the geographic impact of Chakiath Jose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chakiath Jose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chakiath Jose more than expected).

Fields of papers citing papers by Chakiath Jose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chakiath Jose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chakiath Jose. The network helps show where Chakiath Jose may publish in the future.

Co-authorship network of co-authors of Chakiath Jose

This figure shows the co-authorship network connecting the top 25 collaborators of Chakiath Jose. A scholar is included among the top collaborators of Chakiath Jose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chakiath Jose. Chakiath Jose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa). 2024 ·Journal of Clinical Oncology ·Tamim Niazi, Paul L. Nguyen, Scott Williams, Martin R. Stockler, Andrew Martin, Lisa G. Horvath, (unknown), (unknown), Felicia Roncolato, Tee Lim, Chakiath Jose, Jarad Martin, Hans T. Chung, Annie Ébacher, Scott C. Morgan, Simon Hughes, Sean M. McBride, Paul Kelly, Ian D. Davis, Christopher J. Sweeney, (unknown)	2
2	Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial 2018 ·European Urology ·(unknown), Gordana Jovic, Claire Murphy, Cyril Fisher, Isabel Syndikus, Chakiath Jose, Christopher Scrase, John D. Graham, David Nicol, Matthew R. Sydes, David P. Dearnaley	15
3	The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART 2014 ·Radiotherapy and Oncology ·Farshad Foroudi, Daniel Pham, Aldo Rolfo, Mathias Bressel, Colin Tang, (unknown), Sandra Turner, George Hruby, Stephen B. Williams, Dickon Hayne, Margot Lehman, Marketa Skala, Chakiath Jose, (unknown), Tomas Kron	37
4	Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial breakdown → 2014 ·The Lancet Oncology ·David P. Dearnaley, Gordana Jovic, Isabel Syndikus, Vincent Khoo, Richard Cowan, John D. Graham, Edwin Aird, David Bottomley, Robert Huddart, Chakiath Jose, J. H. Matthews, Jeremy Millar, Claire Murphy, John M. Russell, Christopher Scrase, Mahesh Parmar, Matthew R. Sydes	344
5	A P hase III trial to investigate the timing of radiotherapy for prostate cancer with high‐risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage ( RAVES ) trial 2014 ·British Journal of Urology ·Maria Pearse, Carol Fraser‐Browne, Ian D. Davis, Gillian Duchesne, Richard Fisher, Mark Frydenberg, Annette Haworth, Chakiath Jose, David Joseph, Tee Lim, John Matthews, Jeremy Millar, Mark Sidhom, Nigel Spry, Colin Tang, Sandra Turner, Scott Williams, Kirsty Wiltshire, Henry H. Woo, Andrew Kneebone	80
6	What is optimal timing of post prostatectomy radiotherapy? Is adjuvant radiotherapy equivalent to early salvage radiotherapy? The “RAVES” phase III randomized clinical trial. 2012 ·Journal of Clinical Oncology ·Maria Pearse, Andrew Kneebone, Gillian Duchesne, Richard Fisher, Carol Fraser‐Browne, Mark Frydenberg, Annette Haworth, Chakiath Jose, David Joseph, Tee Lim, John Matthews, Jeremy Millar, Mark Sidhom, Nigel Spry, Colin Tang, Sandra Turner, Scott Williams, Kirsty Wiltshire, Henry H. Woo, Ian D. Davis	1
7	Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial breakdown → 2007 ·The Lancet Oncology ·David P. Dearnaley, Matthew R. Sydes, John D. Graham, Edwin Aird, David Bottomley, Richard Cowan, Robert Huddart, Chakiath Jose, J. H. Matthews, Jeremy Millar, Andrea Moore, Rachel C. Morgan, John M. Russell, Christopher Scrase, Richard Stephens, Isabel Syndikus, Mahesh Parmar	686
8	The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397) 2007 ·Radiotherapy and Oncology ·David P. Dearnaley, Matthew R. Sydes, Ruth E. Langley, John D. Graham, Robert Huddart, Isabel Syndikus, J. H. Matthews, Christopher Scrase, Chakiath Jose, John Logue, Richard Stephens	51
9	Estimation of Radiation-Induced Interphase Cell Death in Cultures of Human Tumor Material and in Cell Lines 2003 ·Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ·Elaine S. Marshall, Bruce C. Baguley, J. H. Matthews, Chakiath Jose, (unknown), James H. Shaw, (unknown), Randall P. Morton, (unknown), Michael Rice, Richard Isaacs, Richard D. Coutts, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact